Abstract: The present invention relates to a compound according to Formula (1a) or (1b): wherein R1; R3; Y and X are defined herein, and their use in methods of nucleic acid synthesis.

Abstract: A portable, self-contained beverage apparatus includes a container assembly having a known storage capacity for storing a consumable liquid, and a dispensing assembly disposed within the container assembly that dispenses variable, non-zero quantities of additives into the consumable liquid. The dispensing assembly includes multiple apertures structured and arranged to retain vessels containing the additives to be dispensed into the consumable liquid. The beverage apparatus also includes a level sensor disposed within the container assembly that determines a consumable liquid level of the consumable liquid stored in the container assembly. In certain embodiments, one or more positive displacement pumping mechanisms are configured to pump additive liquid from additive containers into a beverage chamber.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.

Abstract: Techniques are disclosed for using a genetic algorithm to identify a processing pipeline that transforms spectra into a form usable to generate predicted characteristics of corresponding samples. The genetic algorithm is used to generate and evaluate multiple candidate solutions specifying various pre-processing and machine-learning-processing configurations. The processing pipeline is defined based on the candidate solutions.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.

Abstract: A secure communication management (SCM) computer device for providing secure data connections in an aviation environment which, includes safety of flight information, is provided. The SCM computer device includes a processor in communication with a memory. The processor is programmed to receive, from a first user computer device, a first data message for a first aircraft. The first data message is in a standardized data format. The processor is also programmed to analyze the first data message for potential cybersecurity threats. If the determination is that the first data message does not contain a cybersecurity threat, the processor is further programmed to convert the first data message into a first data format associated with the first aircraft and transmit the converted first data message to the first aircraft using a first communication protocol associated with the first aircraft.

Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: The invention relates to the field of food supplement manufacture and therapeutic manufacture. In particular, the invention relates to use of a prebiotic whole plant fibre extract from sugarcane in the diet of an individual for the prophylaxis and/or treatment of Inflammatory Bowel Disease. The invention also relates to a combination of the prebiotic whole plant fibre extract from sugarcane and probiotic strains, the synbiotic use of said combination in the diet of an individual, and the improved outcomes of the synbiotic approach in the prophylaxis and/or treatment of Inflammatory Bowel Disease.

Abstract: A system and method for emergency notification comprising a notification module that transmits a message to a pre-established contact when one or more conditions are met.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: A system and method for emergency notification comprising a notification module that transmits a message to a pre-established contact when one or more conditions are met.

Abstract: A particulate desulfurization material includes one or more copper compounds supported on a zinc oxide support material, wherein the desulfurization material has a copper content in the range 0.1 to 5.0% by weight and a tapped bulk density ?1.55 kg/l. The material is obtained by (i) mixing a powdered copper compound with a particulate zinc support material comprising zinc oxide and one or more precursors that form zinc oxide upon calcination, and one or more binders to form a copper-containing composition, (ii) shaping the copper-containing composition by granulation, and (iii) drying and calcining the resulting granulated material.

Abstract: A secure communication management (SCM) computer device for providing secure data connections in an aviation environment which, includes safety of flight information, is provided. The SCM computer device includes a processor in communication with a memory. The processor is programmed to receive, from a first user computer device, a first data message for a first aircraft. The first data message is in a standardized data format. The processor is also programmed to analyze the first data message for potential cybersecurity threats. If the determination is that the first data message does not contain a cybersecurity threat, the processor is further programmed to convert the first data message into a first data format associated with the first aircraft and transmit the converted first data message to the first aircraft using a first communication protocol associated with the first aircraft.

Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.